FGFR4 and prostate carcinoma: Additionally, the FGFR4 p.(Gly388Arg) variant, located in the transmembrane domain, has been correlated with poorer overall and progression-free survival in Sq-NSCLC patients with lymph node involvement [31]; this can be linked to increased FGFR4 stability and sustained activation, as has been shown in prostate cancer [32].